| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| BOLT | BOLT | Shares | USD | XNCM |
| TIDM | Instrument | Type | Currency | Venue |
|---|---|---|---|---|
| BOLT | BOLT | Shares | USD | XNCM |
Bolt Biotherapeutics, Inc. develops immunotherapies aimed at treating cancer by harnessing the innate immune system. The company utilizes its Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform to create product candidates that combine tumor-targeting antibodies with immune-stimulating payloads. Bolt's pipeline includes BDC-4182, which targets claudin 18.2 in various cancers, and it is engaged in clinical trials and partnerships to advance its therapeutic programs.
No recent RNS announcements for BOLT across BOLT.
No recent RNS announcements for BOLT across BOLT.